139. CRISPR 101 – Starting the Conversation about Gene Editing
Gene editing of our food continues to make news, but the groundbreaking pace of newly published research on human genome editing is unprecedented. Over the past few years, CRISPR-Cas9 has been used in human clinical trials to study potential therapies for a wide range of diseases such as cancer and sickle cell anemia. This interview-format session will explore the functionality and use of gene editing tools, the ethical hurdles the technology faces, and the role it may play in human health. It provides a foundation and framework for further exploration of gene editing tools at future FNCEs.
Planned with the Committee for Lifelong Learning
- Describe CRISPR and other gene editing tools in terms of what they are and how they work
- Cite the importance of knowing what parts of the genome are responsible for different diseases, and recognize the potential of genome editing for treating and preventing disease in humans.
- Identify at least two ways in which CRISPR and gene editing might be used in clinical practice and be able to distinguish between gene editing and gene therapy.
Learning Need Codes:
- 2050 Genetics, nutrigenomics
- 2060 Immunology
- 1020 Computer, electronic technology
- 7.3.1 Recognizes the environmental implications of infectious diseases, compromised health conditions and outbreaks and identifies and implements required preventive action for public safety.
- 8.1.2 Applies knowledge of food and nutrition as well as the biological, physical and social sciences in practice.
- 9.4.7 Demonstrates competent use of technology to enhance the learning experience and delivery of information.
Meghan Adler, MS, RDN, FAND
Food Surveys Research Group / BHNRC / ARS / USDA
Neville Sanjana, PhD
Core Faculty Member
New York Genome Center